Most men with secondary hypogonadism start enclomiphene at 6.25 to 12.5 mg daily, with 12.5 mg the common practical starting point and 6.25 mg the more conservative option favored in the BSSM 2026 position statement. Labs get rechecked at 4 to 6 weeks, morning fasting testosterone plus LH and FSH, before any dose increase. Maintenance typically lands between 12.5 and 25 mg, with 50 mg reserved for inadequate responders. Unlike testosterone therapy, enclomiphene keeps the pituitary signal turned on, which matters if fertility is part of the plan.
TL;DR:
- Starting doses range from 6.25 mg to 12.5 mg daily, with labs checked after 4 to 6 weeks to guide titration; higher doses are for non-responders.
- Testosterone levels often reach 520 to 604 ng/dL at 25 mg daily within six weeks, with quick hormonal response visible even at 14 days.
- Dose escalation should stop if estradiol levels become elevated, adverse effects appear, or LH fails to rise despite increasing the dose.
- Enclomiphene works by stimulating the body’s natural hormone signaling, preserving fertility, and is generally well-tolerated at standard doses.
- Cost for compounded enclomiphene typically ranges from $50 to $120 for a 30-day supply, with daily oral dosing being the standard protocol.
The dose-response curve for enclomiphene isn’t guesswork. It’s mapped in real trial data, and that data should drive every decision about when to hold a dose steady and when to push it higher.
The foundational study here comes from Wiehle and colleagues in 2013, who randomized men with secondary hypogonadism to 6.25, 12.5, or 25 mg daily. After six weeks, mean total testosterone at the 25 mg dose reached roughly 604 ng/dL, with LH rising in step with the dose. That’s the core finding that justifies titrating up rather than jumping straight to a high dose: the response scales predictably, and a single morning testosterone draw reliably reflects a man’s 24-hour hormone exposure, so you don’t need repeated blood draws throughout the day to know where someone stands.
A separate short-term trial reported in Fertility and Sterility looked at an even earlier checkpoint, day 14, and found dose-dependent increases across three strengths: 12.5 mg produced testosterone around 412 ng/dL, 25 mg reached about 520 ng/dL, and 50 mg pushed to roughly 589 ng/dL (all figures are means with meaningful variation between patients). That data point matters because it shows meaningful hormonal movement happens fast, often within two weeks, even though most protocols wait longer before making a titration call.
Dose-Response Snapshot: At 25 mg daily, testosterone commonly lands in the 520 to 604 ng/dL range depending on how many weeks of treatment have passed, based on the Wiehle 2013 and Fertility and Sterility trial data.
The BSSM’s 2026 position statement translates this trial data into a starting framework: begin at 6.25 mg daily, increase weekly as tolerated up to 25 mg daily, and consider escalation up to 50 mg daily only if clinical or biochemical response remains inadequate. That’s a more gradual ramp than many clinics use in practice, and it reflects a bias toward the minimum effective dose rather than maximum hormonal output.
In practice, two titration pathways cover most patients:
Neither path is objectively correct. The conservative route suits men who are side-effect sensitive or have borderline lab values to begin with; the pragmatic route suits men with clearly low testosterone and a strong desire to see faster movement.
Escalation should stop when sensitive estradiol testing indicates elevated levels, a new adverse effect emerges, or LH does not rise as expected despite dose increases. That last one is the most overlooked. If LH does not rise, this may suggest an incorrect diagnosis or inadequate pituitary response; increasing dose further offers no benefit and only raises hormone exposure.
Enclomiphene is a selective estrogen receptor modulator (SERM). It blocks estrogen receptors in the hypothalamus, which the brain reads as a signal that estrogen is low. That triggers a rise in gonadotropin-releasing hormone, which in turn drives LH and FSH output from the pituitary. Higher LH stimulates the testes to produce more of their own testosterone, and higher FSH supports sperm production.
That mechanism is the entire reason enclomiphene differs from testosterone replacement therapy. TRT delivers hormone from the outside and shuts down the body’s own signaling. Enclomiphene works the opposite direction. It amplifies the natural signal, which is why testosterone rises without suppressing LH and FSH, and why fertility is generally preserved rather than compromised.
It’s also worth separating enclomiphene from its older relative, clomiphene. Clomiphene citrate is a racemic mixture of two isomers, zuclomiphene and enclomiphene, and zuclomiphene has a long half-life with weaker estrogenic activity that can blunt the benefit and add side effects over time. Enclomiphene isolates the more active isomer, which is the basis for its more favorable side-effect profile in current use.
Good candidates typically show this pattern:
Red flags that point away from enclomiphene include elevated LH and FSH alongside low testosterone, which suggests primary testicular failure that enclomiphene can’t correct, and any history or imaging finding suggestive of a pituitary lesion, which needs its own workup before hormone therapy of any kind begins.
Every dosing decision on enclomiphene should be backed by a lab result, not a calendar date. Here’s the sequence that keeps titration safe and evidence-based:
Interpreting these results correctly matters as much as ordering them. If LH doesn’t rise after a reasonable trial period, that’s a signal to re-evaluate the pituitary or hypothalamic axis rather than simply raising the dose again, since enclomiphene only works if that axis can respond. A rising estradiol level needs attention too. Because testosterone that rises also aromatizes into estrogen, sensitive estradiol testing is the only way to catch this before it produces symptoms, and management may mean a dose reduction rather than adding another medication. Testosterone that jumps to a supraphysiologic level warrants a dose hold and recheck, not celebration.
Pro Tip: Get your morning testosterone draw before 10 AM and in a fasting state whenever possible. Testosterone follows a daily rhythm, and comparing an early-draw result to an afternoon result from a different visit can make a stable dose look like it’s failing.
Biochemical change and how you feel don’t move on the same clock, and that gap trips up a lot of men who expect symptoms to track lab numbers exactly.
On the lab side, the Wiehle 2013 trial showed meaningful testosterone increases by six weeks across all three dose arms, and the Fertility and Sterility data found measurable rises as early as day 14. That means bloodwork often moves before you’d expect it to. Symptoms tend to lag behind:
Response speed and magnitude aren’t identical for everyone. Body weight matters because higher adiposity increases aromatase activity, converting more testosterone to estrogen and blunting the net effect. Adherence matters too. Missed doses on a daily-dosing regimen create the kind of inconsistent exposure that makes lab results hard to interpret. If symptoms and labs both remain flat after a full trial at an adequate dose, that’s the point to revisit the original diagnosis rather than keep escalating.
Enclomiphene’s side-effect profile in clinical trials is relatively mild at standard doses, but it isn’t zero, and the risk climbs at higher doses.
Reported adverse events in trial data include headache (roughly 1.6%), hot flushes (roughly 1.1%), and nausea (roughly 1.0%), along with occasional muscle spasm and dizziness. These numbers are low, but they aren’t nothing, and they tend to cluster at the upper end of the dosing range.
The 50 mg dose deserves its own mention. Higher doses produce a larger testosterone increase but come with evidence of drug accumulation and a higher side-effect signal, including a greater rate of mood changes and, in rare cases, visual disturbances. That’s the clinical justification for treating 50 mg as an exception reserved for men who haven’t responded adequately at 25 mg, not a default target.
Contraindications that should rule enclomiphene out entirely, or at minimum trigger a specialist referral first:
Drug interactions are a smaller concern with enclomiphene than with many hormone therapies, but anyone on medications metabolized through similar liver pathways should have that reviewed by a prescriber before starting. Ongoing lab monitoring, not just an initial screen, is what actually catches problems early. A one-time clean panel at baseline doesn’t guarantee a clean panel three months later.
Enclomiphene isn’t sold as a mass-market brand-name pill in the U.S. It’s almost always compounded, and that shapes both the price and the practical dosing options available.
Compounding pharmacies typically prepare enclomiphene in 6.25, 12.5, and 25 mg capsule strengths, which lines up neatly with the titration steps used in the trials and the BSSM statement. A 30-day supply commonly runs somewhere between $50 and $120, with the final number depending on the strength prescribed, the specific compounding pharmacy, and the quantity ordered at once. Higher doses and smaller pharmacies tend to sit at the upper end of that range.
Daily dosing is standard, matching how the pivotal trials were structured. That said, some prescribers use alternative patterns, such as every-other-day dosing or a five-days-on, two-days-off schedule, aiming to reduce cumulative side-effect exposure while still maintaining a meaningful average dose. These patterns are pragmatic adjustments rather than approaches backed by their own dedicated trial data, so anyone using them needs the same lab follow-up as someone on standard daily dosing, arguably more, since the response curve is less predictable.
Insurance coverage for compounded enclomiphene is inconsistent. Many men should plan for some out-of-pocket cost, and getting a clear quote from the compounding pharmacy before the first fill avoids surprises. Fertility-focused patients weighing enclomiphene against other paths may also find it useful to look at broader fertility treatment planning resources alongside the hormone-specific decision.
Getting an enclomiphene protocol right depends on consistent access to labs and a prescriber who actually reviews the results before adjusting the dose. That’s the part that’s easy to get wrong outside a structured care setting.
Some telehealth models use a structured cadence involving remote video consultations with licensed providers who assess diagnoses, coordinate baseline lab panels, and set initial doses according to evidence-based protocols. These models may include direct prescription shipping and scheduling follow-up visits aligned with relevant lab checkpoints to guide dosage titration decisions.
Specific services that telehealth providers may offer for enclomiphene care include appointment availability to start baseline evaluations promptly, coordination of lab ordering so results are accessible for dose review, prescription delivery aligned with current dosing rather than standard refill schedules, and ongoing follow-up visits timed around lab checkpoints to evaluate dosing adjustments.
Pro Tip: Bring your most recent testosterone, LH, and FSH results to your first AM Rx visit if you have them. It shortens the time to a first prescription and gives your provider a real trend line instead of a single snapshot.
If you’re weighing enclomiphene against testosterone therapy, AM Rx’s enclomiphene page for low testosterone walks through the eligibility and monitoring differences in more detail.
The instinct with any hormone therapy is to assume more equals better. Enclomiphene punishes that instinct. The trial data is clear that 50 mg produces a bigger testosterone number than 25 mg, but it also comes with more accumulation and a rougher side-effect profile, for a marginal gain that most men never actually need.
The BSSM’s 2026 position statement gets this right by defaulting to the lowest dose that works, with escalation as the exception rather than the plan. That approach also happens to protect the one advantage enclomiphene has over testosterone therapy that nothing else replicates easily: intact fertility. Push the dose too aggressively, chase symptom relief without waiting for labs to confirm the picture, and you lose the careful, stepwise process that makes this drug worth using in the first place. Slower is usually smarter here.
— Bryan
AM Rx removes the two biggest friction points in enclomiphene care: finding a prescriber who follows the lab-driven titration process, and getting timely follow-up once you’re on treatment. A video consult confirms whether your history and prior labs fit the secondary hypogonadism pattern, baseline testing gets ordered right away, and your prescription ships once your provider sets a starting dose.
From there, follow-up visits are scheduled around the 4 to 8 week and 10 to 12 week checkpoints that actually determine whether your dose stays put or moves up, so you’re never guessing whether it’s time for a change. If you want a closer look at how the process works before you commit, the enclomiphene telehealth page breaks down what each visit covers. Ready to move forward? Start your telehealth consent and evaluation to get your first appointment scheduled.
This article is general information, not a substitute for advice from a qualified doctor. Consult a qualified healthcare professional about your own circumstances before acting on anything here.
Most protocols start at 6.25 to 12.5 mg daily, with the BSSM 2026 position statement favoring 6.25 mg as the initial dose before titrating upward based on labs.
Trial data shows measurable testosterone increases as early as 14 days, with more complete hormonal response typically evident by 6 weeks and symptom improvement often following at 8 to 12 weeks.
Most men stabilize between 12.5 and 25 mg daily; 50 mg is used only when response at 25 mg is inadequate, since it carries a higher side-effect signal.
No. Enclomiphene raises LH and FSH rather than suppressing them, which generally preserves fertility, unlike testosterone replacement therapy, which shuts down natural signaling.
A 30-day supply from a compounding pharmacy typically costs between $50 and $120, depending on the prescribed strength and the specific pharmacy.
